Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Bee Venom Compound Tested for Radioprotector Qualities

By BiotechDaily International staff writers
Posted on 23 Jul 2012
A team of Spanish researchers conducted in vitro studies of cytotoxicity to evaluate the optimal concentration level of propolis, in which this natural substance extracted from bee resin would offer the maximum protection against ionized radiation and not be toxic for blood cells.

According to the researchers, from the Technical University of Valencia, the University Hospital La Fe, the University of Valencia, and the Universitat Autonoma de Barcelona, this optimal concentration level is between 120-500 µg/mL. “Within this range can be found maximum protection against radiation-induced damage and the substance does not reveal either a cytotoxicity nor a genotoxicity effect on nonirradiated human lymphocytes,” said Dr. Alegria Montoro, head of the laboratory of biological dosimetry at the University Hospital La Fe.

The conclusions of this study represent a starting point for future clinical applications using propolis. The results were published February 2012 in the journal Food and Chemical Toxicology, and a full revision of the study will be presented at the annual International Conference of the IEEE Engineering in Medicine and Biology Society EMBC12, which will be held in San Diego (CA, USA), in August 2012.

In the study, the researchers utilized four genetic biomarkers, including the mytotic index and the cell proliferation kinetics, with the aim of determining whether propolis has cytotoxic effects on cells. “Using these biomarkers makes it possible to discover how a substance affects cell division: a substance which is cytotoxic and modifies the cell division stage would do so by accelerating, slowing down or even stopping the process, and all three effects are negative,” explained Dr. Alegria Montoro.

The other two biomarkers used are the study of the possible induction of chromosome changesin nonirradiated cultures at different concentration levels and sister chromatid exchanges (SCEs), a genetic biomarker of exposure to chemical agents.

“With this study we already know the in vitro experimental level, the concentration of propolis to be used to make it act as a radiation protector agent, without being cyto/genotoxic for normal cells. This is the first step, a starting point for future clinical assays. The final goal is to develop capsules containing the adequate doses of propolis, but many more hours of research are needed before we are able to do this,” Dr. Alegria Montoro added.

UAB lecturer Francesc Barquinero, currently on leave to work at the Institut de Radioprotection et de Sûreté Nucléaire (IRSN; Fontenay aux Roses, France), participated in the original planning of the study and its design, as well as the interpretation of the findings and posterior contextualization of other studies published.

In 2008, researchers at the Institute for Industrial, Radiophysical and Environmental Safety (ISIRyM) of the Technical University of Valencia and the University Hospital La Fe demonstrated that propolis can reduce by half the damage inflicted on chromosomes by ionized radiations, thereby protecting the DNA from these effects. The new study is essential, according to the investigators, in finding the range of concentrations in which this compound can have a toxic effect on nonirradiated cells.

Related Links:

Technical University of Valencia
University of Valencia
University Hospital La Fe



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.